Can α-synuclein be targeted in novel therapies for Parkinson's disease? - Suppr | 超能文献

Can α-synuclein be targeted in novel therapies for Parkinson's disease?

作者信息

Brundin Patrik, Olsson Roger

出版信息

Expert Rev Neurother. 2011 Jul;11(7):917-9. doi: 10.1586/ern.11.73.

DOI:10.1586/ern.11.73

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Can α-synuclein be targeted in novel therapies for Parkinson's disease?

Expert Rev Neurother. 2011 Jul;11(7):917-9. doi: 10.1586/ern.11.73.

2

Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.聚集缺陷型α-突触核蛋白突变体抑制帕金森病相关α-突触核蛋白变体的纤维化。

Biochem Biophys Res Commun. 2009 Aug 14;386(1):165-9. doi: 10.1016/j.bbrc.2009.06.002. Epub 2009 Jun 6.

3

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.在帕金森病早期，α-突触核蛋白重新分布至黑质中的神经黑素脂质。

Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6.

4

Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.与病理性α-突触核蛋白相关的帕金森病机制：药物研发的新靶点

Neuron. 2006 Oct 5;52(1):33-8. doi: 10.1016/j.neuron.2006.09.026.

5

Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.大鼠黑质中α-突触核蛋白的过表达导致多巴胺能神经元丧失、α-突触核蛋白磷酸化及半胱天冬酶-9激活：类似于帕金森病的致病变化。

J Neurochem. 2004 Oct;91(2):451-61. doi: 10.1111/j.1471-4159.2004.02728.x.

6

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.脑内 α-突触核蛋白在多系统萎缩、帕金森病和进行性核上性麻痹中的蓄积：一项比较性研究。

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

7

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.帕金森病进程中 α-突触核蛋白的溶解性和磷酸化变化。

Acta Neuropathol. 2011 Jun;121(6):695-704. doi: 10.1007/s00401-011-0815-1. Epub 2011 Mar 13.

8

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.帕金森病的发病机制：多巴胺、囊泡与α-突触核蛋白。

Nat Rev Neurosci. 2002 Dec;3(12):932-42. doi: 10.1038/nrn983.

9

The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates.六肽 PGVTAV 可抑制人α-突触核蛋白聚集的神经毒性。

Biochem Biophys Res Commun. 2011 May 6;408(2):334-8. doi: 10.1016/j.bbrc.2011.04.034. Epub 2011 Apr 13.

10

alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.从帕金森病酵母模型的角度看α-突触核蛋白、氧化应激与细胞凋亡

FEMS Yeast Res. 2006 Dec;6(8):1107-16. doi: 10.1111/j.1567-1364.2006.00135.x.

引用本文的文献

1

Metabolic energy decline coupled dysregulation of catecholamine metabolism in physiologically highly active neurons: implications for selective neuronal death in Parkinson's disease.代谢能量下降与生理上高度活跃神经元中儿茶酚胺代谢的失调相关联：对帕金森病中选择性神经元死亡的影响。

Front Aging Neurosci. 2024 Feb 21;16:1339295. doi: 10.3389/fnagi.2024.1339295. eCollection 2024.

2

Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders.外泌体：神经退行性疾病中细胞间通讯的囊泡载体。

Cell Tissue Res. 2013 Apr;352(1):33-47. doi: 10.1007/s00441-012-1428-2. Epub 2012 May 19.

3

Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease.鉴定帕金森病 6-OHDA 大鼠模型中 TID1 表达的双侧变化。

PLoS One. 2011;6(10):e26045. doi: 10.1371/journal.pone.0026045. Epub 2011 Oct 7.